Antipyrine and benzocaine ear drops is a medication for the treatment of ear pain caused by otitis media. It combines antipyrine, an NSAID, and benzocaine, a local anaesthetic in order to treat ear pain, alongside hydroxyquinoline sulfate, an antiseptic and preservative. Its trade names include Auralgan, Aurodex, Auroto,[1] among others, and is abbreviated as A/B otic drops.

Medical uses

A/B otic drops is indicated for ear pain caused by otitis media. It is used every 2–3 hours as needed for pain.[2]

A/B otic drops is also indicated for the removal of excessive or impacted cerumen. To clear cerumen, it is used 3 times a day for 2–3 days.[2]

Ingredients

Each 1 ml of A/B otic drops contains:[2]

Clinical pharmacology

A/B otic drops are effective because antipyrine reduces pain and inflammation and benzocaine numbs the ear.

Reformulation

In 2008, Auralgan was reformulated to include acetic acid and U-polycosanol 410, in addition to antipyrine and benzocaine. Due to this reformulation, pharmacies could no longer substitute the generic antipyrine/benzocaine drops for a prescription written as "Auralgan". The price for the new formulation was roughly $150.00 compared to the generic price of $2.00.[3]

United States ban on manufacture

In 2015, in accordance with their initiative to remove unapproved prescription drugs from the market, the FDA mandated that companies stop manufacturing this drug or be subject to criminal charges. The FDA has not evaluated this drug for safety, effectiveness or quality and has concerns about inappropriate dosing and risk of contamination during the manufacturing process.[4] The FDA adverse event reporting database does not have any known cases of adverse events where Auralgan is the primary suspect.[5]

References

  1. ↑ "ANTIPYRINE WITH BENZOCAINE - OTIC". MedicineNet.com.
  2. 1 2 3 "Auralgan (Antipyrine, Benzocaine, and Glygerin dehydrated) Drug information. Uses, side effects". RxList.com Inc. Archived from the original on October 23, 2008. Retrieved 2008-11-10.
  3. ↑ "The new Auralgan is different from the older Auralgan". Retrieved 2012-06-16.
  4. ↑ "Unapproved Prescription Ear Drop (Otic) Products: Not FDA Evaluated for Safety, Effectiveness and Quality". Food and Drug Administration. Retrieved 2015-10-27.
  5. ↑ "Drug Adverse Event Reporting Database". Retrieved 2015-10-27.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.